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Background. Assessment of treatment response by mea-
suring tumor size is known to be a late and potentially
confounded response index. Serial diffusion MRI has
shown potential for allowing earlier and possibly more
reliable response assessment in adult patients, with
limited experience in clinical settings and in pediatric
brain cancer. We present a retrospective study of clinical
MRI data in children with high-grade brain tumors to
assess and compare the values of several diffusion
change metrics to predict treatment response.
Methods. Eighteen patients (age range, 1.9–20.6 years)
with high-grade brain tumors and serial diffusion MRI
(pre- and posttreatment interval range, 1–16 weeks
posttreatment) were identified after obtaining parental
consent. The following diffusion change metrics were
compared with the clinical response status assessed at
6 months: (1) regional change in absolute and normal-
ized apparent diffusivity coefficient (ADC), (2) voxel-
based fractional volume of increased (fiADC) and
decreased ADC (fdADC), and (3) a new metric based
on the slope of the first principal component of function-
al diffusion maps (fDM).
Results. Responders (n ¼ 12) differed significantly
from nonresponders (n ¼ 6) in all 3 diffusional change
metrics demonstrating higher regional ADC increase,
larger fiADC, and steeper slopes (P, .05). The slope
method allowed the best response prediction (P, .01,
h2 ¼ 0.78) with a classification accuracy of 83% for
a slope of 588 using receiver operating characteristic
(ROC) analysis.
Conclusions. We demonstrate that diffusion change
metrics are suitable response predictors for high-grade pe-
diatric tumors, even in the presence of variable clinical
diffusion imaging protocols.
Keywords: ADC, fDM, pediatric tumor, response
prediction, serial diffusion.
C
urrent assessment of CNS tumor treatment re-
sponse is based on evaluating changes in tumor
size several weeks or months after the end of the
treatment course. Tumor size is generally estimated
from anatomical CT or MRI images,1,2 but volume
changes can occur relatively late than other physiological
changes that may indicate tumor response at an earlier
stage. Furthermore, reduction in the proportion of
active tumor cells during treatment may not necessarily
correlate with lesion dimensions, because there may be
areas of edema and necrosis.3 Therefore, significant
effort is being applied in the development and validation
of functional imaging markers for early response assess-
ment, such as changes in tumor metabolites, diffusion,
or perfusion characteristics.4–6
Diffusion MRI is a widely used technique for both
diagnosis and treatment response. Regional apparent
diffusion coefficient (ADC) changes, estimated from
pre- and posttreatment regions of interest (ROIs), have
been proposed to predict tumor response to radiation/
chemotherapy, with increased ADC associated with
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a more favorable clinical course.7–10 In the limited pedi-
atric literature, decreased diffusion has been reported in
nonresponding diffuse intrinsic brainstem gliomas (after
an initial increase due to radio-therapy effects)11,12 and
nonresponding medulloblastomas.13
Alternatively, individual pixel-to-pixel ADC compar-
isons may provide a more accurate description of tumor
progression by accounting for regional heterogeneity.
Several studies have investigated the value of functional
diffusion maps (fDMs) in predicting tumor response in
adult tumors, time to progression (TTP), and overall
survival (OS) after cytotoxic or anti-angiogenic thera-
pies.4,7,14,15 Typically, the 2 imaging biomarkers ex-
tracted from fDMs are relative volumes exhibiting a
decrease16,17 and an increase4,18 in ADC. This requires
selecting a threshold level that defines what constitutes
an increase or a decrease in ADC. Several studies have
investigated empirically what threshold values may
best separate responders from nonresponders, ranging
from 0.25 to 0.75 × 1023 mm2/s.4,7,14,16 Apart from
the choice of threshold, there are other technical
factors that may affect the calculation of fDM and re-
gional ADC metrics, including image processing steps,
such as registration,19 and the specifics of ROI selec-
tion.16 Furthermore, the majority of fDM and regional
serial ADC analyses published thus far are single-center
prospective studies using consistent imaging protocols
and identical scanners, often limited to a single tumor
type. In clinical practice, however, it is common to en-
counter different acquisition protocols and scanners
among patients and variation in intervals between
follow-up scans. All these factors may confound re-
sponse prediction.
Here, we present the first study, to our knowledge,
that investigates and compares the robustness and suit-
ability of several diffusion change metrics for assessment
of treatment response on highly heterogeneous clinical
pediatric data. We investigate the effects that different
ROI selection, registration technique, and threshold
selection have on fDM metrics and compare these 2 re-
gional metrics. Finally, we present a new postprocessing
method that avoids empirical threshold selection for
fDM analysis by using a Principal Component Analysis
(PCA) on the scatter of pre- and posttreatment
pixel-by-pixel ADC values to infer changes of diffusion
heterogeneity. This new approach removes the need to
estimate the fDM threshold and may help to provide a
simpler and robust tool to assess response.
Materials and Methods
Patients
All patients participating in this study signed informed
consent to have their data collected and used for research
by the UK Child Cancer and Leukaemia Group (CCLG)
Functional Imaging Group database, a UK National
Health Service (NHS) Research Ethics Committee–
approved study. Eighteen patients with high-grade
tumors (World Health Organization [WHO] grade III
and IV) were included (age range, 1.9–20.6 years)
who had undergone 2 diffusion MR scans before
(0.1–6.3 weeks) and after (1–16 weeks) the start of
chemotherapy/radiotherapy as part of clinical care. All
patients had diagnosis confirmed by histology, except
for one patient with a secreting germ cell tumor, as
reviewed by 2 neuro-pathologists with .15 years of ex-
perience. Only patients with residual disease were
included and, thus, excluded any macroscopic complete
resection. Response was defined at 6 months after the be-
ginning of treatment, using combined clinical and radio-
logical criteria according to new Response Assessment
in Neuro-Oncology (RANO) criteria20 assessed by an
experienced pediatric oncologist (R.G.) and neuro-
radiologists (T.J., R.A.D., or D.P.A.). All patients
received standard clinical treatment (Table 1).
MRI
Clinical MRI scans were obtained before and after che-
motherapy and/or radiotherapy as part of clinical care.
The first scan was always performed before the begin-
ning of treatment and/or biopsy. MRI scans were per-
formed on 1 of 3 scanners, a 1.5T GE Sigma (General
Electric Medical Systems, Milwaukee, WI), a 1.5T
Philips Intera, or a 3T Philips Achieva (Philips Medical
Systems, Best, Netherlands), and as part of a multimodal
MRI protocol, that consisted of at least pre- and
postcontrast axial T1-weighted (TR ¼ [598–647] ms,
TE ¼ [12–14] ms 0.45 × 0.45 × 4 mm3 voxel size),
precontrast axial T2-weighted (TR ¼ [3000] ms, TE ¼
[72–85] ms 0.45× 0.45× 4 mm3 voxel size), and diffu-
sion imaging. Diffusion data were obtained with different
sequences, ranging from diffusion-weighted imaging
(DWI) to 15-direction diffusion-tensor imaging (DTI),
using b ¼ 0 s/mm2 and either bmax¼ 1000 s/mm2
or bmax¼ 800 s/mm2, TR¼ [4883–5800] ms, TE ¼
[59–89] ms, and voxel size of either 12 mm3 (2× 2 ×
3) or14.4 mm3 (1.9 × 1.9 × 4).
Additional volunteer data were acquired for each dif-
fusion sequence and used to determine specific fDM
thresholds for each combination of pre-post treatment
scan protocol.
MRI Protocol Comparison
The effect of using different pre- and posttreatment
imaging protocols on diffusion metrics was investigated
for 6 of the cases, in which 2 distinct ADC imaging pro-
tocols were available for one time point by comparing
the respective diffusion distributions in both tumor and
white matter (WM) ROIs.
Manual Tracing of Tumor
Pre- and posttreatment whole-tumor ROIs were manually
drawn on measurable tumors (ie, .1 cm) by an experi-
enced neuro-radiologist (R.A.D.) and a second experi-
enced researcher (M.M.) using NeuROI (The University
of Nottingham, UK; http://www.nottingham.ac.uk/
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scs/divisions/clinicalneurology/software/neuroi.aspx).
Previous studies have used either contrast-enhancing
tissue or abnormal FLAIR areas to define the ROIs,
but it is unclear which is a better predictor of OS.16,19
In this study, tumor tissue was defined on the
contrast-enhanced T1w images as areas of abnormal en-
hancement, but also using the coregistered precontrast
T2w images to identify and exclude blood vessels adja-
cent to enhancing tumor and to include low-contrast
tumor or necrotic tissue adjacent to edema. This
allowed comparing tumor volumes, including enhancing
and nonenhancing tumor parts, by multiplying the areas
from these ROIs with inter-slice distances.
Regional ADC Change Metrics
ADC change was calculated from the ROIs generated for
fDM analysis (see below). Change was expressed as the
post- / pre ratio of mean tumor ADC (ADCr) computed
for each lesion. WM-normalized ratios (nADCr) were
computed using a small reference region in normal-
appearing WM. The advantage of using normalized
ADC is to remove some of the heterogeneity that the
use of different scanners and protocols introduces. The
disadvantages of this normalization are introducing an
unwanted age dependence in the very young patients
and potential bias from disease and treatment effect on
Table 1. Patient demographic characteristics, histopathological tumor diagnosis, and treatment details
Age
(years)
Gender Tumor type Grade Type of
surgery
Treatment
(within scan
window)
Scan
interval
(weeks)1
Volume
change
(at 6
months)
New
lesions
(at 6
months)
RANO
response
(at 6
months)
Clinical course
after end of
therapy
10.7 F Secr. Germ Cell
Tumor
none Chemotherapy/
RT
2.4 decrease N PR No Relapse
2.7 F PNET IV biopsied Chemotherapy
(COG 921)
15.1 no
change
N PD Death
11.7 M Pineoblastoma IV biopsied Chemotherapy
(PNET3)
4.0 decrease N PR No Relapse
8 M Pineal PNET III biopsied Chemotherapy
(PNET3)
6.9 decrease N PR No Relapse
15 M Germinoma III biopsied Radiotherapy 6.4 decrease N CR No Relapse
15.8 F Glioneuronal
tumour
IV debulking Chemotherapy
(Milan)
9.7 decrease N SD Residual Thalamic
tumour
4.6 F DIPG(GBM) IV biopsied Chemotherapy/
RT (TMZ)
10.0 no
change
N PD Death
7.8 F DIPG(GBM) IV biopsied Chemotherapy/
RT (TMZ)
16.7 increase N PD Death
3.5 F MB IV debulking Chemotherapy
(Milan)
4.3 decrease N CR Leptomeningeal
spread
1.9 M MB IV biopsied Chemotherapy
(PNET3)
4.1 decrease N PR Death
6.2 M DIPG
(Glioblastoma)
III biopsied Chemotherapy/
RT (TMZ)
13.1 increase N PD Death
4.7 M MB IV debulking Chemotherapy/
RT (POG
9031)
3.4 decrease Y PR Supra tentorial
recurrent
tumour
9.2 M MB IV debulking Chemotherapy
(Milan)
1.9 decrease N CR No Relapse
12.3 M Germinoma III biopsied Chemotherapy 2.1 decrease N PR No Relapse
12.4 M GBM IV debulking Chemotherapy/
RT (TMZ)
16.9 decrease N PR Death
6.8 M MB IV biopsied Chemotherapy/
RT (POG
9031)
10.0 decrease N PR No Relapse
20.6 M Glioblastoma(GBM) IV biopsied Chemotherapy
(TMZ)
12.6 decrease N SD No Relapse
12.8 F MB IV debulking Chemotherapy
(Milan)
11.3 decrease N PR No Relapse
11.2 F Pineoblastoma IV biopsied Chemotherapy
(PNET3)
8.9 decrease N PR No Relapse
Abbreviations: COG, Children’s Oncology Group; CR, complete response; DIPG, diffuse intrinsic pontine glioma; GBM, glioblastoma
multiforme; MB, medulloblastoma; PD, progressive; PNET, primitive neuroectodermal tumor; POG, Pediatric Oncology Group; PR, partial
response; RANO, Response Assessment in Neuro-Oncology; RT, radiotherapy; SD, stable disease; TMZ, tomozolomide.
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WM that cannot be avoided by choosing normal-
appearing WM (2 of the 18 cases were in recurrent pa-
tients). To better interpret fDM, we also derived peak
height decrease (PkDec) as a heterogeneity measure
from normalized tumor histograms.
Generating Functional Diffusion Maps
The process of generating a fDM involves a series of
sequential processing steps. First, data registration is per-
formed; all pre- and postcontrast data are registered to a
common baseline image (typically anatomic, such as
FLAIR, T2w, or contrast-enhanced T1w). This step
may include linear or nonlinear registration processes.
Second, tumor ROIs are defined; these are delineated
on the basis of the anatomical images and applicable
to the registered diffusion data. Third, the fDM is calcu-
lated using a predefined threshold that determines a suit-
able change in ADC values; pixel-by-pixel change is
classified as increase, no change, or decreased ADC.
Finally, fDM metrics, such as overall volumes of
decrease or increase in ADC, are calculated.
All aforementioned steps contain operator dependen-
cies that may affect the final fDM metrics. Different tests
and processes to assess and minimize the effect of these
are presented below.
fDM Preprocessing: Registration and ROI Definition
All images (both pre- and posttreatment) were spatially
coregistered to the pretreatment T2w images with use
of a mutual information-based affine registration using
FSL’s linear registration tool (FLIRT; FMRIB, Oxford,
UK; http://www.fmrib.ox.ac.uk/fsl/).
Using the same ROIs according to the regional ADC
analysis, 2 types of ROI combinations and registration
were compared for the fDM approach: (1) a combined
ROI from those pixels only included in both pre- and
posttreatment-ROIs and (2) pretreatment ROI only—
in this case, the affine registration was followed by an ad-
ditional nonlinear registration step of the posttreatment
diffusion data, also using FSL. The standard settings of
FSL’s nonlinear registration tool (FNIRT) were used
for comparability with previous studies.19
fDM Metrics
fDMs were computed using in-house software developed
in MATLAB R2010a (The MathWorks Inc., Natick,
MA, 2010). The fraction of decreased (fdADC) and
the fraction of increased (fiADC) ADC were determined
in accordance with methods in previous studies.4,15,18
In addition to fiADC and fdADC, we used their ratio
fDMratio ¼ fiADC/(0.01 + fdADC), with the 0.01
factor introduced to avoid division by zero in those
cases in which there were no decreased diffusion
voxels. All the aforementioned metrics were also com-
puted for normalized ADC, as described above, to
produce corresponding normalized versions: nfiADC,
nfdADC, and nfDMratio.
fDM Thresholds
Although ADC thresholds ranging from 0.25 to 0.75×
1023 mm2/s have been investigated, previous studies have
mostly used 0.5 or 0.4 × 1023 mm2/s4,7,15,18,19,21,22 to
define the no-change ADC level. In addition to these
2 standard thresholds and to assess the effect of hetero-
geneous imaging protocols that contained different scan-
ners, resolution, slice thickness, or diffusion gradient
directions, individual fDM thresholds were computed
for each possible protocol combination, based on the
minimum detectable ADC changes of healthy volunteer
data. This allowed us to determine protocol-pair specific
thresholds that showed no ADC change for 90%, 95%,
and 98% of pixels in a skull-stripped whole-brain ROI.
The range and mean values for these thresholds were
0.2–0.5/0.4 × 1023 mm2/s (90%), 0.3–0.8/0.6 ×
1023 mm2/s (95%), and 0.5–0.9/0.8 × 1023 mm2/s
(98%). For same-protocol combinations, the minimum
detectable thresholds were similar to the literature,23
and they increased for mixed-protocols. For the normal-
ized version of the fDM metrics, all above threshold
values were normalized using the same method as for
the data itself.
A further modification of the fDM approach, the
graded fDM proposed by Ellingson,16 was also tested.
In graded fDMs, both decreasing and increasing diffu-
sion volumes are subclassified into 3 bins: [0.25 to 0.4,
0.4 to 0.75, above 0.75] × 1023 mm2/s for increased
diffusion and [20.25 to 20.4, 20.4 to 20.75, below
20.75] × 1023 mm2/s for decreased diffusion.
Nonthresholded Functional Diffusion Maps
To avoid the problem of empirical fDM threshold se-
lection, we analyzed the pre- and posttreatment ADC
scatter plot (Fig. 1). This scatter plot has been used
previously to show the concept of fDMs, but we are
the first to analyze it quantitatively. The 2D distribu-
tion of this scatter plot holds information on tumor
heterogeneity and its change, and the direction of
largest variance can be computed by PCA. PCA
defines orthogonal linear combinations of variables,
principal components (PC), which describe the largest
amount of variability in the data. In the case of
change in pre- and posttreatment ADC values, the
first principal component can be used to determine
whether the largest variability in ADC values occurs
before or after treatment. If the direction of the first
principal component describes the same variability
before and after treatment (ie, a line y ¼ mx with a
slope m of 1, or an angle of 458), it indicates no
change in heterogeneity of ADC values (ie, the spread
of ADC values would have been unaffected by treat-
ment). A higher slope for the first PC indicates an in-
crease in heterogeneity, and a lower slope indicates a
decrease in heterogeneity. Therefore, we used the
angle of the slope of the first PC on a pre- and post-
treatment ADC change scatter plot to calculate the
change in tumor ADC heterogeneity (Fig. 2).
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Statistical Analysis
Statistical analysis was performed using PASW Statistics
18, release version 18.0.0 (SPSS, Inc.). Paired t tests were
used to compare differences between both tumor and
WM. ADC values calculated using the same imaging
protocol differed with those calculated using different
pre- and posttreatment protocols. Candidate marker dis-
tributions were tested for normality and homogeneity of
variance with use of Shapiro-Wilk and Levene’s test.
Nonnormally distributed fDM candidate response
markers were transformed to normal distributions
with use of log transformation (YT ¼ log10 [Y + 1]).
Analysis of covariance was used to test for differences
in candidate biomarkers between responders and nonre-
sponders, using age as covariate. The significance level
was defined as P, .05. Effect sizes were calculated as
partial-eta squared (h2). ROC curves were used to deter-
mine the best threshold for separating responders and
nonresponders for the slope method.
Results
Quality Control
Differences between fDM analysis for both observers
(M.M. and R.D.) were small, with single-measure
intraclass correlation coefficient for either fiADC
or fdADC. 0.97 on any of the threshold levels.
Similarly, the intraclass correlation coefficient for ADCr
was 0.94.
Fig. 1. Serial MRI in a patient with pineoblastoma showing partial response to chemotherapy. Top row corresponds to pretreatment and
bottom row to posttreatment (1 month) scan data. Left 3 columns: T2, diffusion-weighted and contrast-enhanced T1 images. Right
column: fDM scatter plot for each voxel in the ROI (top) and fDM map (bottom); green voxels indicate an increase in diffusion, red
voxels indicate a decrease in diffusion, and orange voxels indicate no change.
Fig. 2. fDM scatter plots with direction of first principal component (solid line). Left: fDM for a responding MB, showing a first principal
component with high slope, compared with the diagonal (dotted line). Middle: fDM for a responding GBM, showing a first principal
component with high slope, and conventional fDM analysis shows a substantial volume of decreased diffusion (dark grey pixels). Right:
fDM for a nonresponding PNET, showing a first principal component with low slope. Light gray voxels indicate an increase in diffusion,
dark gray voxels indicate a decrease in diffusion, and medium gray voxels indicate no change.
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Regional ADC measures derived from different pro-
tocols acquired during the same scan (6 pairs) did not
differ significantly (mean difference [range] for tumor:
0.02 × 1023 mm2/s [0.005–0.34] × 1023 and for WM
0.01 × 1023 mm2/s [0.002–0.23] × 1023).
Treatment Effect
Tumor volumes significantly decreased by a mean of
30% from baseline (mean [range] 26.0 cm3 [3.5–
60.1]) to the posttreatment scan (17.6 cm3, range
[1.8–49.8]; paired t test P, .05). There was an overall
increase in diffusion due to treatment, with an ADCr
increase (mean+SD) of 24%+25% and an nADCr
increase of 26%+20%.
Response Prediction
At 6 months after treatment, 12 patients were classed as
responders (complete or partial response) and 6 as non-
responders (stable or progressive disease) (Table 1). At
this time, the observed tumor volume decrease was
not significantly different (Mann-Whitney, P . .05)
between responders and nonresponders (Table 2).
Baseline ADC measures (mean ADC and normalized
mean ADC) were not significantly different between re-
sponders and nonresponders (P . .05).
Both ADCr and nADCr were higher in responders
than in nonresponders. This increase was significant
in nADCr (P ¼ .03) and not significant in ADCr
(Table 2).
Conventional fDMs
The best fDMratio to differentiate between responders
and nonresponders (P ¼ .01) was found using the fixed
threshold of 0.4 × 1023 mm2/s, affine registration, a
combined pre-/post-treatment ROI, and normalized
ADC (Table 3). fDMratio proved to be robust against
use of different threshold levels (using either the variable
98% or 0.4 or 0.5 × 1023 mm2/s), registration method,
and ADC normalisation (Table 4). ROC analysis sug-
gested an optimum threshold ,2.0 for identifying nonre-
sponse to treatment using fDMratio (sensitivity¼ 78%,
specificity ¼ 83%). The best fiADC (P ¼ .02) was also
obtained using the 0.4 × 1023 mm2/s threshold, normal-
ized ADC, but nonlinear registration. fiADC results were
more dependent on image processing than fDMratios
(Table 4).
fdADC was mostly unable to significantly differenti-
ate between responders and nonresponders, as were
the candidate biomarkers calculated using the variable
90% and 95% thresholds (Table 4).
Similarly, none of the 6 metrics based on volumes
of diffusion change (3 decreasing and 3 increasing sub-
volumes) for the graded fDM approach significantly
differentiated between responders and nonresponders
(P . .05).
Slope of Nonthresholded fDMs
The angle of the slope of the first principal component
was higher in responders than in nonresponders
(Table 3). This difference using normalized ADC was
significant (P ¼ .01), and the separation between them
was clearer than in the thresholded fDM methods
(h2 ¼ 0.76). ROC analysis suggested an optimum
threshold ,588 for identifying nonresponse to treatment
yielding the best accuracy because of slightly better sen-
sitivity than fDMratio (sensitivity ¼ 83%, specificity ¼
83%). The slope method using nonnormalised ADC per-
formed similarly (P ¼ .01, h2 ¼ 0.68).
Table 3. Bestperforming fDM-based candidate biomarkers (with
nfiADC and nfDMratio calculated using a 0.4 × 1023 mm2/s
threshold [normalized], affine registration and pre- and
posttreatment ROIs).
Candidate
biomarker
Responders
mean (+SD)
Non-responders
mean (+SD)
P h2
nfiADC 37.0 (+23.9) 10.5 (+8.4) .02 0.30
nfDMratio 14.4 (+11.8) 1.0 (+1.2) .01 0.51
Slope 75.98 (+12.88) 47.48 (+7.88) .01 0.76
Slope method was calculated using normalized ADC.
Abbreviations: h2, partial eta squared; nfDMratio, normalized
fDMratio; nfiADC, fraction of increased normalized ADC.
Table 2. Differences between responders and nonresponders in patient demographic characteristics and regional diffusion candidate
biomarkers.
Variable Responders mean+ SD,
or mean [range]
non-responders mean+ SD,
or mean [range]
P h2
Age (years) 9.1 (+4.1) 9.6 (+7.0) NS –
Scan time (weeks after treatment) 6.4 [1.0–16.2] 6.9 [2.4–12.3] NS –
Volume decrease (%) 33 (+35) 25 (+21) NS –
Baseline ADC (×1023 mm2/s) 1.0 (+0.2) 1.1 (+0.2) NS –
Baseline nADC 1.2 (+0.2) 1.5 (+0.2) NS –
ADCr (% increase) 30 (+27) 2 (+19) 0.08 –
nADCr (% increase) 35 (+23) 3 (+16) 0.03 0.38
Significance and effect size (for significant candidate biomarkers only). Abbreviations: ADCr, ADC ratio; h2, partial eta squared if
significant; nADC, normalized ADC; nADCr, normalized ADC ratio; NS, not significant.
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Discussion
We investigated the suitability of various serial diffusion
metrics to predict treatment response in children with
high-grade brain tumors who had undergone heteroge-
neous clinical diffusion protocols. Separation of treat-
ment responders and nonresponders was feasible at
8-week intervals with most diffusion metrics, with best
results (83% accuracy) achieved for a novel slope of
the first principal component followed by the ratio of
voxels with increased over decreased diffusion. This
suggests that increase in diffusion heterogeneity and
preferential increase in diffusivity are associated with
treatment response. These results are in line with the
scarce previous work in the pediatric literature.13,24
As expected, fDM metrics yielded higher effect sizes
than regional ADC changes. Regional ADC changes
were only significantly higher in responders than in non-
responders when normalized to white matter. This nor-
malization step was not necessary for significance in the
fDM metrics, thus avoiding the introduction of age
dependence because of white matter maturation or a
nonspecific treatment effect on white matter diffusivity.
fDM Metrics
We found that fDMratio, which combines information
from both fdADC and fiADC, produced the best
results, compared with previously proposed functional
diffusion metrics. fdADC and fiADC results have been
published on high-grade tumor gliomas, with changes
in fdADC (but not fiADC) indicative of overall survival
in patients after cytotoxic or anti-angiogenic treat-
ment.15,17 In contrast, fiADC (but not fdADC) has
been shown to predict overall survival in the same type
of tumor after similar imaging protocols except radio-
therapy.18,25 One might speculate that a combined
marker such as fDMratio might prove to be more
robust to treatment type. We confirmed that registra-
tion19 and ROI selection16,19 and choice of threshold
values14 can affect the performance of response
prediction. The diagnostic accuracy of the best discrimi-
nating metric, fDMratio, was largely unaffected by the
different applied methodologies, such as the use of differ-
ent threshold levels, ROI selection, registration method,
or ADC normalization (Table 4).
fDM Thresholds
Both fixed thresholds of 0.5 and 0.4 × 1023 mm2/s and
the variable 98% threshold were sensitive to detecting
the clinical response status, and lower variable thresh-
olds (90% and 95%) were not. For the imaging protocol
combinations tested here, the 98% threshold reflects in-
dividual threshold values of 0.2–0.5 × 1023 mm2/s.
The graded fDM approach suggests that intermediate
diffusion decreases at 0.25–0.4 × 1023 mm2/s would
be more sensitive to relevant biological change in
tumor cellularity, as opposed to change in nonspecific
edema.16 This could not be replicated in this study
(neither for decreased nor increased diffusion subvo-
lumes), perhaps because of a more heterogeneous
dataset.
Slope of Nonthresholded fDM
To quantify the information of the fDM scatter plots
without using empirical thresholds, we investigated the
diagnostic value of the slope of the first principal compo-
nent. This way, we determined the change in largest data
variability, which proved to be the best indicator of
treatment response among all the fDM-based methods.
The slope of the first PC afforded clinically useful dis-
crimination of 83% with use of an angle of 588 as
cutoff. Of importance, prediction of tumor response to
treatment with use of nonthresholded fDMs eliminates
the need to define a diffusion change threshold, which
is dependent on a number of factors that cannot
always be controlled and is difficult to generalize. For
example, one of the problems with nonrigid registration
fDMs is that the literature standard thresholds calculat-
ed on nondeformed data14 should be recalculated using
Table 4. Functional diffusion mapping for predicting response in pediatric high-grade tumors: effects of different metrics and
postprocessing steps.
Threshold (31023 mm2/s) ROI/registration nfiADC nfdADC fDMratio nfDMratio
P h2 P h2 P h2 P h2
Fixed 0.5 Pre and post/affine .04 0.26 .36 – .01 0.48 .01 0.49
Pre-treat./non-rigid .05 0.24 .02 0.31 .01 0.42 .01 0.42
Fixed 0.4 Pre and post/affine .03 0.26 .26 – .01 0.48 .01 0.51
Pre-treat./non-rigid .02 0.30 .55 – .01 0.42 .01 0.39
Variable 98% Pre and post/affine .02 0.28 .39 – .01 0.45 .01 0.44
Pre-treat./non-rigid .06 – .33 – .01 0.43 .01 0.46
Variable 95% Pre and post/affine .26 – .73 – .04 0.23 .05 0.26
Pre-treat./non-rigid .08 – .49 – .06 – .07 –
Variable 90% Pre and post/affine .43 – .79 – .34 – .34 –
Pre-treat./non-rigid .51 – .64 – .26 – .25 –
Significance and effect size (for significant metrics only). Abbreviations: fDMratio, fiADC to fdADC ratio; h2, partial eta squared; nfdADC,
fraction of decreased normalized ADC; nfDMratio, normalized fDMratio; nfiADC, fraction of increased normalized.
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the nonrigid registration method, because their suitabil-
ity largely depends on the extent of the deformation that
is applied. These thresholds would need to be recalculat-
ed for any changes on the deformation parameters or al-
gorithm. The new approach of determining the slope of
nonthresholded fDMs eliminates this problem.
Limitations
There are several limitations of the current study. We
only studied a small and heterogeneous sample size, a
common problem in single-center pediatric studies that
reflects the relative low incidence of pediatric brain
tumors (3 per 100 000 children per year).26 This
problem is aggravated by heterogeneous tumor types,
presence of postsurgical residue, treatment protocols,
and follow-up intervals. Thus, our presented findings
have to be considered as preliminary but are likely to
be more representative of clinical settings and may
even address some multi-center scanner and protocol
variability. Nevertheless, despite these limitations, we
were able to clearly separate responders from nonre-
sponders with a range of serial diffusion metrics. One
may speculate that, with more homogeneous image ac-
quisition and tumor type sample, it may be possible to
further stratify responders into complete and partial re-
sponse and nonresponders into stable and progressive
disease with use of fDM biomarkers, which was not pos-
sible in this dataset.
Moreover, we included datasets relatively long after
treatment initiation (median, 9 weeks; range, 1–16
weeks), in contrast to fDM adult studies assessed at
318 or 6 weeks.16 At longer intervals, fDM analysis
becomes less relevant as volume reduction in responders
becomes visible in conventional MR. Although our
study cannot be extrapolated to earlier time points, a pre-
vious pediatric study suggested that changes in ADC can
predict radiotherapy response as early as one week.10
An important question for our heterogeneous clinical
dataset was to assess and, if need be, control for the
effect of using a mix of ADC maps from 15-direction
DTI to single-direction DWI. For those patients in
whom both different and same pre- and posttreatment
protocols were available, the differences in fDM bio-
markers were found to be not significant. Because this
was only a limited small subgroup of the data, the
effect was further investigated by using normalized
ADC values and by using fDM thresholds specific to
each pre- and posttreatment protocol. Although stand-
ardization of protocols is clearly preferable, our study
provides some evidence that mixing of protocols is feasi-
ble and did not mask differential treatment effects in re-
lation to clinical response.
There is increasing evidence that diffusion metrics
may contribute to differentiate true progression from
pseudo-progression. In this study, there were 3 patients
with increased enhancing tumor volume who were
later classified as responders. Two of these were correct-
ly classed as responders with use of fDM metrics.
However, these are only small numbers with variable
time intervals and variable treatments, factors that
will affect the prevalence and detection of pseudo-
progression.
Conclusion
To the best of our knowledge, this is the first study that
investigated the use of fDM-based biomarkers of treat-
ment response in pediatric high-grade brain tumors.
Even in the presence of clinical and technical heterogene-
ity, our results suggest that fDM techniques are superior
to regional ADC change assessment and provide suitable
imaging biomarkers to predict tumor response. A new
fDM analysis technique based on the slope of the first
principal component yielded the best results with an
overall diagnostic accuracy of 83% to separate respond-
ers from nonresponders.
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